GIP Side Effects: What Studies Report

What "GIP" refers to in the published literature

Glucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone released from the gut after nutrient intake. A 2024 review in Frontiers in Endocrinology described GIP and GLP-1 as gut-derived incretins whose receptors have been targeted by single and dual receptor agonists developed for type 2 diabetes and obesity, with insulin secretion occurring in a glucose-dependent manner (Frontiers in Endocrinology, 2024).

That distinction matters for any question about adverse events. The clinical literature almost never studies GIP by itself in humans. Instead, it studies molecules that engage the GIP receptor together with the GLP-1 receptor (dual agonists such as tirzepatide) or together with GLP-1 and glucagon receptors (triple agonists such as retatrutide). Every tolerability signal described below therefore belongs to a combination molecule, not to GIP in isolation, and the literature does not separate which receptor produced which effect.

Where the safety data actually come from

The largest structured safety dataset in this space concerns tirzepatide, a dual GIP and GLP-1 receptor agonist. Its first-in-class description reported that the molecule LY3298176 progressed from discovery to clinical proof of concept in type 2 diabetes, with gastrointestinal events identified as the most commonly observed adverse events in early clinical study (Molecular Metabolism, 2018). A 2022 systematic review and meta-analysis in Diabetologia pooled randomised trials of tirzepatide at 5 mg, 10 mg and 15 mg once weekly in type 2 diabetes and reported both glycaemic and body-weight changes alongside a higher frequency of gastrointestinal adverse events than comparators (Diabetologia, 2022).

Additional safety framing comes from narrative and regulatory-facing reviews: a 2023 clinical review of tirzepatide in AJHP summarised its pharmacology, efficacy and adverse-effect profile for practitioners (AJHP, 2023), and a 2024 Diabetes Care review examined efficacy and safety across GLP-1-based medicines used for type 2 diabetes and obesity (Diabetes Care, 2024).

Gastrointestinal Events: What Studies Report

Across the incretin literature, gastrointestinal effects dominate the adverse-event tables. The 2022 meta-analysis reported that nausea, vomiting and diarrhoea occurred more often with tirzepatide 5 mg, 10 mg and 15 mg weekly than with placebo comparators in type 2 diabetes trials, and that discontinuation for adverse events was also more frequent than with placebo (Diabetologia, 2022). The 2023 clinical review characterised adverse effects of the dual agonist as predominantly gastrointestinal, most apparent during dose escalation (AJHP, 2023).

A 2025 expert review of tirzepatide in overweight and obesity likewise described gastrointestinal events — nausea, vomiting, diarrhoea and constipation — as the principal tolerability issue reported in the obesity trial programme, generally mild to moderate in severity (Expert Opinion on Pharmacotherapy, 2025). A 2024 review of incretin-based agents in metabolic dysfunction-associated steatohepatitis reported the same pattern across GLP-1, GIP/GLP-1 and glucagon/GLP-1 receptor agonist classes, naming gastrointestinal intolerance as the recurring limitation (World Journal of Gastroenterology, 2024).

Dose relationship

Researchers have repeatedly described these events as dose-related. The early clinical development report of the dual GIP/GLP-1 agonist noted gastrointestinal adverse events increasing with higher exposures during phase 2 evaluation (Molecular Metabolism, 2018), and the pooled analysis of 5 mg, 10 mg and 15 mg weekly dosing reported a similar gradient across dose groups (Diabetologia, 2022). This is why trial protocols in that literature used stepwise escalation schedules rather than starting at target doses.

Hypoglycaemia: What Studies Report

Because incretin-driven insulin secretion is glucose-dependent, reviews describing the mechanism of GIP and GLP-1 receptor agonism noted that insulinotropic activity falls as glucose falls (Frontiers in Endocrinology, 2024). In the pooled trial data, hypoglycaemia was reported largely in relation to background glucose-lowering therapy rather than as an isolated effect of the dual agonist itself (Diabetologia, 2022). The 2023 clinical review discussed the same consideration when the agent was combined with insulin or sulfonylureas in people with type 2 diabetes (AJHP, 2023).

Labelled Warnings and Rarer Events: What Studies Report

The 2023 clinical review of tirzepatide summarised labelled safety information for the approved product, including the boxed warning derived from thyroid C-cell tumour findings in rodents and cautions relevant to pancreatic and gallbladder events (AJHP, 2023). The 2024 Diabetes Care review examined safety questions raised for the broader GLP-1-based class, discussing how frequently such events appeared in trials versus post-marketing reports and where uncertainty remained (Diabetes Care, 2024). These are regulatory and pharmacovigilance descriptions of specific approved medicines; they are not statements about GIP the hormone.

Cardiovascular Outcomes: What Studies Report

Dedicated cardiovascular outcome evidence for a GIP-containing molecule was still accumulating at the time of the verified publications. A 2024 design and baseline-characteristics paper described SURPASS-CVOT, a trial comparing tirzepatide with dulaglutide for major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease (American Heart Journal, 2024). That publication reported the trial's structure and enrolled population rather than outcome results, so cardiovascular safety conclusions cannot be drawn from it.

Triple Agonists Containing GIP Activity: What Studies Report

Molecules adding glucagon receptor activity to GIP and GLP-1 agonism have been described in early clinical work. The discovery-to-proof-of-concept report for LY3437943, a triple glucagon, GIP and GLP-1 receptor agonist, described its pharmacology and first clinical evaluation for glycaemic control and weight loss, with gastrointestinal events again the most commonly observed adverse events (Cell Metabolism, 2022). A 2025 review of retatrutide summarised the same class pattern, reporting gastrointestinal adverse events as the most frequent and generally dose-dependent finding in published trials (Biomolecules, 2025).

Comparison of what each source reported

What the literature does not answer

Several gaps are worth stating plainly rather than filling with inference:

• Standalone GIP in humans. The verified literature summarised here contains no controlled human safety trial of GIP administered alone as a therapeutic. Adverse-event profiles described above belong to multi-receptor agonists.
• Attribution by receptor. Because tirzepatide engages two receptors, published trials cannot separate which adverse events arose from GIP receptor activity and which from GLP-1 receptor activity (Frontiers in Endocrinology, 2024).
• Research-grade peptides. Materials labelled as GIP or GIP analogues supplied for laboratory use are not approved medicines, and no human tolerability dataset for such materials appears in the verified papers cited here.
• Long-term outcomes. Pipeline reviews of obesity pharmacotherapy described numerous incretin-based candidates still in phase 2 and phase 3 development, meaning long-term comparative safety for many GIP-containing molecules remained incomplete (Expert Opinion on Investigational Drugs, 2025) (International Journal of Obesity, 2025).

How researchers framed tolerability in trial design

Reviews of the obesity pipeline noted that tolerability, not only efficacy, shaped how these agents were developed and compared, with gradual dose escalation used to manage gastrointestinal events reported in earlier phases (International Journal of Obesity, 2025). The 2024 Diabetes Care review similarly reported that discontinuation rates and adverse-event frequencies were central endpoints when comparing incretin-based medicines (Diabetes Care, 2024). Readers comparing sources should note that meta-analyses pool heterogeneous trials, that review articles restate primary data rather than generate it, and that design papers such as the SURPASS-CVOT publication report methods rather than findings (American Heart Journal, 2024).

Educational note

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question, medication or symptom. It summarises what published studies reported about adverse events associated with molecules acting at the GIP receptor and does not describe how any substance should be used.

References

• Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists (Frontiers in Endocrinology, 2024)
• Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis (Diabetologia, 2022)
• GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis (World Journal of Gastroenterology, 2024)
• Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics (American Heart Journal, 2024)
• Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity (Diabetes Care, 2024)
• Tirzepatide: Clinical review of the "twincretin" injectable (AJHP, 2023)
• The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines (Expert Opinion on Investigational Drugs, 2025)
• Retatrutide-A Game Changer in Obesity Pharmacotherapy (Biomolecules, 2025)
• LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept (Molecular Metabolism, 2018)
• LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept (Cell Metabolism, 2022)
• Tirzepatide for overweight and obesity management (Expert Opinion on Pharmacotherapy, 2025)
• What is the pipeline for future medications for obesity? (International Journal of Obesity, 2025)